Endocrinology
Podcast: Diabetes Triple Distilled. Pitfalls of A1c testing, different guidelines for A1C targets, when and how to use the newer medications such as SGLT-2 inhibitors and GLP-1 agonists, and more
24 Nov, 2020 | 09:03h | UTC#243 Diabetes Triple Distilled – The Curbsiders Internal Medicine Podcast
Systematic review: Ultra-long‐acting insulins provide modest benefit compared to NPH insulin for Type 2 DM, resulting in reduced risk of hypoglycemia but no difference in HbA1c
23 Nov, 2020 | 09:45h | UTC
#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and CKD. Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo
18 Nov, 2020 | 09:08h | UTCSotagliflozin in Patients with Diabetes and Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and Recent Worsening Heart Failure. Diarrhea and severe hypoglycemia were more common with sotagliflozin than with placebo
18 Nov, 2020 | 09:06h | UTCSotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure – New England Journal of Medicine (link to abstract – $ for full-text)
Opinion: A new important study supports wider use of the polypill
18 Nov, 2020 | 09:01h | UTCRichard Smith: A new important study supports wider use of the polypill – The Lancet
Original study and commentaries: Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk
Commentary on Twitter
"We seem now to have good evidence that the polypill can reduce cardiovascular events and deaths by at least a third and probably by half in those who take the polypill regularly" @Richard56 discusses a new study in @NEJM https://t.co/B2tkN4pkDP
— The BMJ (@bmj_latest) November 17, 2020
[Abstract Only] In a Phase 2 randomized trial, Semaglutide at high doses improved Nonalcoholic Steatohepatitis (NASH), but with no significant beneficial effects in liver fibrosis
17 Nov, 2020 | 09:31h | UTCA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Semaglutide Shows Promise in NASH Phase 2 Study – Medscape (free registration required)
Commentary on Twitter
Patients with nonalcoholic steatohepatitis were randomly assigned to receive subcutaneous semaglutide or placebo. The incidence of NASH resolution was significantly higher with semaglutide than with placebo. #LiverMtg20
— NEJM (@NEJM) November 13, 2020
#AHA20 – Randomized trial: In patients with refractory hypercholesterolemia, the use of Evinacumab significantly reduced the LDL levels. Larger studies with patient-relevant outcomes are needed.
16 Nov, 2020 | 01:59h | UTCEvinacumab in Patients with Refractory Hypercholesterolemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In patients with hypercholesterolemia that is refractory to statin and PCSK9 inhibitor therapy, the use of evinacumab reduced plasma lipid levels by 50%. #AHA20
— NEJM (@NEJM) November 15, 2020
#AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo
16 Nov, 2020 | 01:57h | UTCCommentary: ‘Nocebo effect’ cause of most statin side-effects, study suggests – The Guardian
Original study: N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects – New England Journal of Medicine ($ – no abstract available)
Commentary on Twitter
Patients who had discontinued statins because of side effects received four bottles of a statin, four bottles of placebo, and four empty bottles. Each used for 1 month, in random sequence. The symptom burden with placebo was 90% of the symptom burden with the statin. #AHA20
— NEJM (@NEJM) November 15, 2020
#AHA20 – Randomized trial: High-dose Omega-3 fatty acids did not reduce the risk of cardiac events in patients at high cardiovascular risk
16 Nov, 2020 | 01:51h | UTCEditorial 2: Do Omega-3 Fatty Acids Benefit Health?
Commentary on Twitter
In this RCT, omega-3 fatty acids (EPA/DHA) did not reduce major adverse CV events vs corn oil in statin-treated patients at high CV risk
(Compare w Vascepa in REDUCE-IT) https://t.co/7BIs1Rr8YZ#STRENGTHTrial #AHA20 #SteveNissen@ProfSNicholls @Dmozaffarian @ClevelandClinic— JAMA (@JAMA_current) November 15, 2020
[Not Published Yet] #AHA20 – Randomized trial: Fish oil and vitamin D supplements not effective for preventing atrial fibrillation
16 Nov, 2020 | 01:49h | UTCCommentary: Fish Oil, Vitamin D Don’t Prevent A-fib: VITAL Rhythm – TCTMD
World Diabetes Day 2020 (14 November 2020): Introducing the Global Diabetes Compact
16 Nov, 2020 | 01:43h | UTCWorld Diabetes Day 2020: Introducing the Global Diabetes Compact – World Health Organization
See also: WHO Global Diabetes Compact
Related: The Lancet Commission on diabetes: using data to transform diabetes care and patient lives (free registration required) AND Editorial: Turning evidence into action on diabetes – The Lancet
Commentary on Twitter (thread – click for more)
It's #WorldDiabetesDay #COVID19 causes fear & suffering for people with #diabetes:
1⃣ They have ↗️ risk of severe disease & death when infected with COVID-19
2⃣ Delay in diagnosis may result in more advanced disease & complications
3⃣ Delayed, incomplete, interrupted treatment pic.twitter.com/vlL9XAXVqq— World Health Organization (WHO) (@WHO) November 14, 2020
KDIGO Guideline Synopsis: Diabetes management in chronic kidney disease. Use of ACE inhibitors or ARBs, glycemic monitoring and targets, and choice of antihyperglycemic drugs are covered
11 Nov, 2020 | 09:09h | UTCOriginal guideline: Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Perioperative evaluation and management of patients with diabetes, thyroid disease, and adrenal insufficiency. Use of insulin and noninsulin diabetic medications, management of hyper and hypothyroidism, and use of stress-dose corticosteroids are some of the subjects reviewed
10 Nov, 2020 | 09:24h | UTCPerioperative Evaluation and Management of Endocrine Disorders – Mayo Clinic Proceedings
Low carbohydrate diet: Insights from a general practice service in patients with type 2 diabetes
4 Nov, 2020 | 09:38h | UTC
Commentary on Twitter
PUBLISHED! We wanted to showcase what a low-carb approach could achieve for people with #T2D in UK NHS general practice Our @BMJNutrition paper published today. Open access PLEASE read it https://t.co/zxj2XESBaO HUGE thanks to patients and staff @nnedpro Hurrah! pic.twitter.com/BLML1vSA6i
— Dr David Unwin (@lowcarbGP) November 3, 2020
Social determinants of health and diabetes: A scientific review
3 Nov, 2020 | 03:07h | UTCSocial Determinants of Health and Diabetes: A Scientific Review – Diabetes Care
Cohort study: Dietary inflammatory potential and risk of cardiovascular disease among men and women in the U.S.
3 Nov, 2020 | 03:05h | UTCCommentary: High Intake of Proinflammatory Foods Linked to CVD Risk – NEJM Journal Watch∗
[Abstract Only] Cohort study: Sodium–Glucose Cotransporter-2 Inhibitors and the risk for diabetic ketoacidosis
3 Nov, 2020 | 03:01h | UTCCommentarios: Can You Spot Euglycemic DKA From SGLT-2 Inhibitors? – Journal Feed AND Sodium glucose cotransporter-2 inhibitor use associated with increased risk of diabetic ketoacidosis – 2 Minute Medicine
Study provides new estimates of breast cancer risks associated with different hormone replacement therapy preparations
30 Oct, 2020 | 01:04h | UTCCommentaries: Study provides new estimates of breast cancer risks associated with HRT – University of Oxford AND New estimates of breast cancer risks associated with HRT – The BMJ AND HRT: Breast Ca Risk Tied to Hormone Type, Duration of Tx – Physician’s Weekly
Systematic review: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
29 Oct, 2020 | 08:57h | UTCSummary: PCSK9 inhibitors for prevention of cardiovascular disease – Cochrane Library
[Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes
25 Oct, 2020 | 23:34h | UTCEffect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Finerenone Linked to Reduced Cardiorenal Events for Chronic Kidney Disease – HCPLive
Commentary on Twitter (thread – click for more)
‼️Effect of Finerenone on CKD outcomes in T2DM
⚡️Finerenone decreased risk of CKD progression by 18%
⚡️Finerenone decreased CV morbidity & mortality by 14%
Published in @NEJM today https://t.co/XvshpZZCK4@ASNKidney #Kidneywk pic.twitter.com/FOkxnG1enz
— Aisha Shaikh (@aishaikh) October 23, 2020
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
20 Oct, 2020 | 01:33h | UTCExecutive summary: 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment – Kidney International
Commentary on Twitter
2020 #KDIGO Diabetes Management in #CKD Guidelinehttps://t.co/G127PgO1fe@deboerih @P_Rossing @goKDIGO pic.twitter.com/3kVNDpAoub
— Kidney International (@Kidney_Int) October 4, 2020
Life expectancy after bariatric surgery in the Swedish Obese Subjects Study
16 Oct, 2020 | 09:29h | UTCCommentary: Higher average life expectancy after obesity surgery – University of Gothenburg
Commentary on Twitter
This long-term study compared mortality and life expectancy among patients who underwent bariatric surgery or received usual obesity care in the Swedish Obese Subjects study and in persons in the SOS reference study.
— NEJM (@NEJM) October 15, 2020
Review: Evaluation and treatment of patients with hypercortisolism
16 Oct, 2020 | 09:24h | UTCEvaluation and Treatment of Patients With Hypercortisolism: A Review – JAMA Surgery
Meta-analysis: Nonpharmacologic interventions for reducing blood pressure in adults with prehypertension to established hypertension
14 Oct, 2020 | 09:20h | UTC
Commentary on Twitter
Which lifestyle intervention works best for hypertension? #Bayesian meta-analysis suggests the #DASH diet https://t.co/1CgLVwN4LB #AHAJournals @tinauchojo pic.twitter.com/wzJ87OPT0m
— JAHA (@JAHA_AHA) October 5, 2020
Why people with diabetes are being hit so hard by Covid-19
8 Oct, 2020 | 09:04h | UTCWhy people with diabetes are being hit so hard by Covid-19 – STAT